Reckitt Benckiser Group plc Logo

Reckitt Benckiser Group plc

RB.SW

(1.8)
Stock Price

78,14 GBP

19.12% ROA

18.53% ROE

34.43x PER

Market Cap.

54.750.666.360,00 GBP

101.05% DER

1.7% Yield

11.19% NPM

Reckitt Benckiser Group plc Stock Analysis

Reckitt Benckiser Group plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Reckitt Benckiser Group plc Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (27.67%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

3 Dividend

The company's consistent dividend payouts over the past five years exemplify its strong commitment to providing shareholders with reliable returns, making it an attractive investment option.

4 DER

The stock has a reasonable amount of debt compared to its ownership (94%), suggesting a balanced financial position and a moderate level of risk.

5 PBV

The stock's high Price-to-Book Value (P/BV) ratio (4.75x) suggests it's overvalued, potentially making it an expensive investment.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

10 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-4.520) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Reckitt Benckiser Group plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Reckitt Benckiser Group plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Buy
4 Stoch RSI Buy

Reckitt Benckiser Group plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Reckitt Benckiser Group plc Revenue
Year Revenue Growth
2002 3.454.000.000
2003 3.713.000.000 6.98%
2004 3.871.000.000 4.08%
2005 4.179.000.000 7.37%
2006 4.922.000.000 15.1%
2007 5.269.000.000 6.59%
2008 6.563.000.000 19.72%
2009 7.753.000.000 15.35%
2010 8.453.000.000 8.28%
2011 9.485.000.000 10.88%
2012 9.567.000.000 0.86%
2013 10.043.000.000 4.74%
2014 8.836.000.000 -13.66%
2015 8.874.000.000 0.43%
2016 9.891.000.000 10.28%
2017 11.512.000.000 14.08%
2018 12.597.000.000 8.61%
2019 12.846.000.000 1.94%
2020 13.993.000.000 8.2%
2021 13.234.000.000 -5.74%
2022 14.453.000.000 8.43%
2023 14.322.000.000 -0.91%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Reckitt Benckiser Group plc Research and Development Expenses
Year Research and Development Expenses Growth
2002 54.000.000
2003 57.000.000 5.26%
2004 66.000.000 13.64%
2005 63.000.000 -4.76%
2006 82.000.000 23.17%
2007 88.000.000 6.82%
2008 102.000.000 13.73%
2009 119.000.000 14.29%
2010 33.000.000 -260.61%
2011 26.000.000 -26.92%
2012 171.000.000 84.8%
2013 199.000.000 14.07%
2014 146.000.000 -36.3%
2015 140.000.000 -4.29%
2016 149.000.000 6.04%
2017 187.000.000 20.32%
2018 223.000.000 16.14%
2019 257.000.000 13.23%
2020 288.000.000 10.76%
2021 313.000.000 7.99%
2022 325.000.000 3.69%
2023 674.000.000 51.78%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Reckitt Benckiser Group plc General and Administrative Expenses
Year General and Administrative Expenses Growth
2002 0
2003 0 0%
2004 0 0%
2005 0 0%
2006 313.000.000 100%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 491.000.000 100%
2013 692.000.000 29.05%
2014 528.000.000 -31.06%
2015 575.000.000 8.17%
2016 648.000.000 11.27%
2017 728.000.000 10.99%
2018 890.000.000 18.2%
2019 740.000.000 -20.27%
2020 1.393.000.000 46.88%
2021 1.190.000.000 -17.06%
2022 1.205.000.000 1.24%
2023 2.824.000.000 57.33%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Reckitt Benckiser Group plc EBITDA
Year EBITDA Growth
2002 679.000.000
2003 787.000.000 13.72%
2004 879.000.000 10.47%
2005 980.000.000 10.31%
2006 1.024.000.000 4.3%
2007 1.347.000.000 23.98%
2008 1.639.000.000 17.82%
2009 2.032.000.000 19.34%
2010 2.288.000.000 11.19%
2011 2.556.000.000 10.49%
2012 2.594.000.000 1.46%
2013 2.523.000.000 -2.81%
2014 3.892.000.000 35.17%
2015 2.421.000.000 -60.76%
2016 2.626.000.000 7.81%
2017 5.715.000.000 54.05%
2018 3.401.000.000 -68.04%
2019 3.840.000.000 11.43%
2020 4.602.000.000 16.56%
2021 3.969.000.000 -15.95%
2022 3.936.000.000 -0.84%
2023 3.252.000.000 -21.03%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Reckitt Benckiser Group plc Gross Profit
Year Gross Profit Growth
2002 1.776.000.000
2003 1.978.000.000 10.21%
2004 2.121.000.000 6.74%
2005 2.293.000.000 7.5%
2006 2.789.000.000 17.78%
2007 3.072.000.000 9.21%
2008 3.890.000.000 21.03%
2009 4.664.000.000 16.6%
2010 5.121.000.000 8.92%
2011 5.662.000.000 9.55%
2012 5.537.000.000 -2.26%
2013 5.969.000.000 7.24%
2014 5.096.000.000 -17.13%
2015 5.246.000.000 2.86%
2016 6.026.000.000 12.94%
2017 6.870.000.000 12.29%
2018 7.635.000.000 10.02%
2019 7.778.000.000 1.84%
2020 8.435.000.000 7.79%
2021 7.676.000.000 -9.89%
2022 8.361.000.000 8.19%
2023 8.672.000.000 3.59%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Reckitt Benckiser Group plc Net Profit
Year Net Profit Growth
2002 408.000.000
2003 489.000.000 16.56%
2004 577.000.000 15.25%
2005 669.000.000 13.75%
2006 674.000.000 0.74%
2007 938.000.000 28.14%
2008 1.120.000.000 16.25%
2009 1.418.000.000 21.02%
2010 1.568.000.000 9.57%
2011 1.745.000.000 10.14%
2012 1.829.000.000 4.59%
2013 1.739.000.000 -5.18%
2014 3.223.000.000 46.04%
2015 1.743.000.000 -84.91%
2016 1.832.000.000 4.86%
2017 6.172.000.000 70.32%
2018 2.161.000.000 -185.61%
2019 -2.772.000.000 177.96%
2020 1.187.000.000 333.53%
2021 -52.000.000 2382.69%
2022 2.330.000.000 102.23%
2023 804.000.000 -189.8%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Reckitt Benckiser Group plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2002 1
2003 1 0%
2004 1 0%
2005 1 0%
2006 1 0%
2007 1 100%
2008 2 0%
2009 2 0%
2010 2 50%
2011 2 0%
2012 3 0%
2013 2 0%
2014 4 50%
2015 2 -100%
2016 3 0%
2017 9 75%
2018 3 -166.67%
2019 -4 200%
2020 2 400%
2021 0 0%
2022 3 100%
2023 1 -200%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Reckitt Benckiser Group plc Free Cashflow
Year Free Cashflow Growth
2002 340.000.000
2003 370.000.000 8.11%
2004 612.000.000 39.54%
2005 695.000.000 11.94%
2006 929.000.000 25.19%
2007 819.000.000 -13.43%
2008 1.086.000.000 24.59%
2009 1.771.000.000 38.68%
2010 1.158.000.000 -52.94%
2011 1.513.000.000 23.46%
2012 1.711.000.000 11.57%
2013 1.896.000.000 9.76%
2014 1.915.000.000 0.99%
2015 1.605.000.000 -19.31%
2016 2.029.000.000 20.9%
2017 2.142.000.000 5.28%
2018 2.017.000.000 -6.2%
2019 968.000.000 -108.37%
2020 3.032.000.000 68.07%
2021 1.247.000.000 -143.14%
2022 1.954.000.000 36.18%
2023 748.500.000 -161.06%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Reckitt Benckiser Group plc Operating Cashflow
Year Operating Cashflow Growth
2002 439.000.000
2003 526.000.000 16.54%
2004 695.000.000 24.32%
2005 773.000.000 10.09%
2006 1.017.000.000 23.99%
2007 953.000.000 -6.72%
2008 1.302.000.000 26.8%
2009 1.929.000.000 32.5%
2010 1.525.000.000 -26.49%
2011 1.718.000.000 11.23%
2012 1.888.000.000 9%
2013 2.121.000.000 10.99%
2014 2.099.000.000 -1.05%
2015 1.784.000.000 -17.66%
2016 2.422.000.000 26.34%
2017 2.491.000.000 2.77%
2018 2.454.000.000 -1.51%
2019 1.411.000.000 -73.92%
2020 3.518.000.000 59.89%
2021 1.697.000.000 -107.31%
2022 2.397.000.000 29.2%
2023 850.500.000 -181.83%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Reckitt Benckiser Group plc Capital Expenditure
Year Capital Expenditure Growth
2002 99.000.000
2003 156.000.000 36.54%
2004 83.000.000 -87.95%
2005 78.000.000 -6.41%
2006 88.000.000 11.36%
2007 134.000.000 34.33%
2008 216.000.000 37.96%
2009 158.000.000 -36.71%
2010 367.000.000 56.95%
2011 205.000.000 -79.02%
2012 177.000.000 -15.82%
2013 225.000.000 21.33%
2014 184.000.000 -22.28%
2015 179.000.000 -2.79%
2016 393.000.000 54.45%
2017 349.000.000 -12.61%
2018 437.000.000 20.14%
2019 443.000.000 1.35%
2020 486.000.000 8.85%
2021 450.000.000 -8%
2022 443.000.000 -1.58%
2023 102.000.000 -334.31%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Reckitt Benckiser Group plc Equity
Year Equity Growth
2002 1.196.000.000
2003 1.470.000.000 18.64%
2004 1.577.000.000 6.79%
2005 1.855.000.000 14.99%
2006 1.863.000.000 0.43%
2007 2.383.000.000 21.82%
2008 3.292.000.000 27.61%
2009 4.012.000.000 17.95%
2010 5.058.000.000 20.68%
2011 5.711.000.000 11.43%
2012 5.921.000.000 3.55%
2013 6.334.000.000 6.52%
2014 6.832.000.000 7.29%
2015 6.904.000.000 1.04%
2016 8.421.000.000 18.01%
2017 13.533.000.000 37.77%
2018 14.742.000.000 8.2%
2019 9.407.000.000 -56.71%
2020 9.159.000.000 -2.71%
2021 7.453.000.000 -22.89%
2022 9.483.000.000 21.41%
2023 8.469.000.000 -11.97%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Reckitt Benckiser Group plc Assets
Year Assets Growth
2002 3.512.000.000
2003 3.820.000.000 8.06%
2004 3.852.000.000 0.83%
2005 4.213.000.000 8.57%
2006 5.737.000.000 26.56%
2007 5.868.000.000 2.23%
2008 9.182.000.000 36.09%
2009 8.661.000.000 -6.02%
2010 13.422.000.000 35.47%
2011 14.126.000.000 4.98%
2012 15.080.000.000 6.33%
2013 15.149.000.000 0.46%
2014 15.496.000.000 2.24%
2015 15.268.000.000 -1.49%
2016 18.019.000.000 15.27%
2017 37.013.000.000 51.32%
2018 37.650.000.000 1.69%
2019 32.139.000.000 -17.15%
2020 31.292.000.000 -2.71%
2021 26.946.000.000 -16.13%
2022 28.742.000.000 6.25%
2023 27.136.000.000 -5.92%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Reckitt Benckiser Group plc Liabilities
Year Liabilities Growth
2002 2.304.000.000
2003 2.346.000.000 1.79%
2004 2.272.000.000 -3.26%
2005 2.357.000.000 3.61%
2006 3.871.000.000 39.11%
2007 3.483.000.000 -11.14%
2008 5.888.000.000 40.85%
2009 4.647.000.000 -26.71%
2010 8.292.000.000 43.96%
2011 8.345.000.000 0.64%
2012 9.158.000.000 8.88%
2013 8.813.000.000 -3.91%
2014 8.662.000.000 -1.74%
2015 8.362.000.000 -3.59%
2016 9.593.000.000 12.83%
2017 23.440.000.000 59.07%
2018 22.861.000.000 -2.53%
2019 22.732.000.000 -0.57%
2020 22.133.000.000 -2.71%
2021 19.493.000.000 -13.54%
2022 19.259.000.000 -1.22%
2023 18.667.000.000 -3.17%

Reckitt Benckiser Group plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
20.29
Net Income per Share
2.27
Price to Earning Ratio
34.43x
Price To Sales Ratio
3.75x
POCF Ratio
21.34
PFCF Ratio
23.93
Price to Book Ratio
6.66
EV to Sales
4.25
EV Over EBITDA
17.19
EV to Operating CashFlow
23.57
EV to FreeCashFlow
27.15
Earnings Yield
0.03
FreeCashFlow Yield
0.04
Market Cap
54,75 Bil.
Enterprise Value
62,13 Bil.
Graham Number
24.48
Graham NetNet
-21.4

Income Statement Metrics

Net Income per Share
2.27
Income Quality
1.6
ROE
0.19
Return On Assets
0.06
Return On Capital Employed
0.18
Net Income per EBT
0.68
EBT Per Ebit
0.72
Ebit per Revenue
0.23
Effective Tax Rate
0.31

Margins

Sales, General, & Administrative to Revenue
0.1
Research & Developement to Revenue
0.02
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.6
Operating Profit Margin
0.23
Pretax Profit Margin
0.16
Net Profit Margin
0.11

Dividends

Dividend Yield
0.02
Dividend Yield %
1.7
Payout Ratio
0.82
Dividend Per Share
1.33

Operating Metrics

Operating Cashflow per Share
3.66
Free CashFlow per Share
3.18
Capex to Operating CashFlow
-0.13
Capex to Revenue
-0.02
Capex to Depreciation
-0.89
Return on Invested Capital
0.13
Return on Tangible Assets
0.19
Days Sales Outstanding
42.6
Days Payables Outstanding
136.96
Days of Inventory on Hand
102.19
Receivables Turnover
8.57
Payables Turnover
2.66
Inventory Turnover
3.57
Capex per Share
-0.48

Balance Sheet

Cash per Share
1,61
Book Value per Share
11,73
Tangible Book Value per Share
-14.05
Shareholders Equity per Share
11.73
Interest Debt per Share
12.02
Debt to Equity
1.01
Debt to Assets
0.31
Net Debt to EBITDA
2.04
Current Ratio
0.64
Tangible Asset Value
-10,12 Bil.
Net Current Asset Value
-13,37 Bil.
Invested Capital
1.01
Working Capital
-3,04 Bil.
Intangibles to Total Assets
0.68
Average Receivables
1,71 Bil.
Average Payables
2,19 Bil.
Average Inventory
1637000000
Debt to Market Cap
0.16

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Reckitt Benckiser Group plc Dividends
Year Dividends Growth
2015 2
2016 2 0%
2017 2 0%
2018 2 50%
2019 2 -100%
2020 2 0%
2021 2 0%
2022 2 0%
2023 2 50%
2024 1 -100%

Reckitt Benckiser Group plc Profile

About Reckitt Benckiser Group plc

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom, the United States, China, India, and internationally. The company offers acne treatment creams, facial washes, and cleansing pads; disinfection, hygiene, and first aid products; condoms, sex toys, and lubricants; heartburn and indigestion solutions; and cough and chest congestion, multi-symptom, and sinus remedies for adults and children under the Clearasil, Dettol, Durex, Gaviscon, and Mucinex brands. It also provides analgesics; sore throat medications; and hair removal products under the Nurofen, Strepsils, and Veet brands. In addition, the company offers fragrances and devices; water softeners; home cleaning products; dish washes; toilet cleaners; disinfectants; sprays, baits, and plug-ins for pest control; stain removals; fabric washing; and other hygiene products under the Air Wick, Calgon, Cillit Bang, Finish, Harpic, Lysol, Mortein, Vanish, and Woolite brands, as well as analgesics, adult nutrition products, iron-fortified hypoallergenic baby formula, products for joint issues, and infant and toddler nutrition products, as well as vitamins, minerals, and supplements under the Biofreeze, Airborne, Mead Johnson, Move Free, Enfamil, and Nutramigen brands. Further, it provides probiotics, sore throat pain relief products, Omega products, brain health support products, cleaning and carpet cleaning products, septic tank system treatment products, cough syrups, plant-based laundry products, probiotics, and lubricants under the Digestive Advantage, Cepacol, MegaRed, Neuriva, Easy-Off, RID-X, Delsym, Botanical Origin, Bodi-Ome, and K-Y brands. The company was founded in 1819 and is headquartered in Slough, the United Kingdom.

CEO
Mr. Kristoffer Loe Licht
Employee
40.000
Address
Turner House
Slough, SL1 3UH

Reckitt Benckiser Group plc Executives & BODs

Reckitt Benckiser Group plc Executives & BODs
# Name Age
1 Mr. Fabrice Beaulieu
Chief Marketing, Sustainability & Corporate Affairs Officer
70
2 Mr. Ranjay Radhakrishnan
Chief Human Resources Officer
70
3 Ms. Angela Naef Ph.D.
Chief Research & Development Officer
70
4 Mr. Filippo Catalano
Chief Information & Digitisation Officer
70
5 Mr. Volker Kuhn
President of Hygiene
70
6 Mr. Richard Joyce
Head of Investor Relations
70
7 Ms. Shannon Sue Eisenhardt
Chief Financial Officer & Executive Director
70
8 Mr. Kristoffer Loe Licht
Chief Executive Officer & Executive Director
70
9 Mr. Sami Naffakh
Chief Supply Officer
70
10 Ms. Catheryn O'Rourke
Senior Vice President, General Counsel & Company Secretary
70

Reckitt Benckiser Group plc Competitors